The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that ten company-sponsored abstracts will be presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands being held on 13–16 June.
Data from the rheumatology portfolio includes latest research findings on Stelara® (ustekinumab), an anti-interleukin (IL)-12/23 monoclonal antibody, in the treatment of active systemic lupus erythematosus (SLE). Janssen will present two abstracts which evaluate the efficacy and safety as well as the SLE Disease Activity Index 2000 (SLEDAI-2K) and SLEDAI-2K Responder Index-50 (SRI-50) responses of ustekinumab in patients with SLE.
Presentations of note for guselkumab include three abstracts from the Phase 2 study of guselkumab in active psoriatic arthritis patients.
Wim Noel, Medical Affairs Director Rheumatology, EMEA at Janssen-Cilag NV said, “At Janssen we are committed to addressing the unmet needs of people living with rheumatic diseases today and in the future. We’re looking forward to presenting the latest data from our portfolio and pipeline at this prestigious conference.”